The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

[1] Davies MJ(2018)Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 61 2461-2498

[2] D’Alessio DA(2018)Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-2701

[3] Fradkin J(2005)Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes Diabet Med 22 1016-1023

[4] Davies MJ(2011)LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects Diabetes Obes Metab 13 434-438

[5] D'Alessio DA(2011)A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes Diabetes Obes Metab 13 426-433

[6] Fradkin J(2014)Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 384 1349-1357

[7] Feinglos MN(2016)Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers Postgrad Med 128 810-821

[8] Saad MF(2019)Change in HbA1c across the baseline HbA1c range in type 2 diabetes patients receiving once-weekly dulaglutide versus other incretin agents Diabetes Ther 10 1113-1125

[9] Pi-Sunyer FX(2013)Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study Health Qual Life Out. 11 217-424

[10] An B(2016)Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme Diabetes Obes Metab 18 419-2295

[1] Davies MJ(2018)Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 61 2461-2498

[2] D’Alessio DA(2018)Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-2701

[3] Fradkin J(2005)Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes Diabet Med 22 1016-1023

[4] Davies MJ(2011)LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects Diabetes Obes Metab 13 434-438

[5] D'Alessio DA(2011)A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes Diabetes Obes Metab 13 426-433

[6] Fradkin J(2014)Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 384 1349-1357

[7] Feinglos MN(2016)Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers Postgrad Med 128 810-821

[8] Saad MF(2019)Change in HbA1c across the baseline HbA1c range in type 2 diabetes patients receiving once-weekly dulaglutide versus other incretin agents Diabetes Ther 10 1113-1125

[9] Pi-Sunyer FX(2013)Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study Health Qual Life Out. 11 217-424

[10] An B(2016)Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme Diabetes Obes Metab 18 419-2295